Spring House, PA, United States of America

Michael Naso

USPTO Granted Patents = 26 

 

 

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 124(Granted Patents)


Location History:

  • Union, NJ (US) (1989 - 1990)
  • Philadelphia, PA (US) (2008 - 2012)
  • Radnor, PA (US) (2011 - 2017)
  • Spring House, PA (US) (2013 - 2019)
  • Swarthmore, PA (US) (2020 - 2021)

Company Filing History:


Years Active: 1989-2025

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents

Title: Michael Naso - Innovator in Antibody Engineering

Introduction

Michael Naso, based in Spring House, Pennsylvania, is a prominent inventor with a remarkable portfolio comprising 25 patents. His groundbreaking work in the field of antibody engineering has led to substantial advancements in therapeutic technology, particularly in cancer treatment.

Latest Patents

Among his latest patents, Naso has developed innovative antigen-binding regions against fibronectin type III domains. This includes Fibronectin type III (FN3) domain antibodies and polynucleotides capable of encoding these antibodies, which have vast applications including the engineering of FN3 domain-targeting chimeric antigen receptors (CARs). The methods he has patented not only outline the creation of these FN3 domain antibodies and CARs but also the engineered immune cells used to combat diseases such as cancer. Another significant patent focuses on BCMA-specific fibronectin type III domains and the development of BCMA-targeting CARs, alongside engineered immune cells expressing these CARs, thus furthering potential treatments for cancer through advanced immunotherapy.

Career Highlights

Naso has had a distinguished career, having worked with notable companies such as Janssen Biotech, Inc. and Centocor, Inc. His innovative approaches have positioned him at the forefront of research and development in his field, paving the way for novel treatment methodologies.

Collaborations

Michael has collaborated with esteemed colleagues, including Bernard Scallon and Natalie Fursov. These partnerships have played a crucial role in the successful implementation of his research initiatives and have enhanced the potential applications of his inventions in therapeutic contexts.

Conclusion

Michael Naso is a leading innovator whose contributions are shaping the future of cancer therapies through antibody engineering. With his extensive patent portfolio and collaborative efforts, he continues to push the boundaries of medical research and innovation, making significant strides towards improved healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…